Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
131.5 USD | -1.07% | +2.74% | +20.62% |
01:45am | Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer | CI |
26/06 | Merck: US approval for canine flu vaccine | CF |
MarketScreener Strategies
Merck and Company : Leader in oncology, modest valuation | October 29, 2019 at 08:34 pm IST |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- MarketScreener Strategies